Developer docs
API playgroundTry for free, no card

Search company profiles

Medcura

Full company profile

uuid0000xl8

Namestring
Medcura
Legal namestring
Medcura, Inc.
Websiteurl
medcurainc.com
Company typeenum
Private
Founded yearint
2019
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRiverdale, United States
HQ citystring
Riverdale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hemostatic agents, wound care products, surgical medical devices, biopolymer hemostasis, bleeding control solutions
Industry1 code
PRIMARYCRADAMAB
First Aid & Wound Care (Bandages, Dressings, Antiseptics, Burn Care)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Surgical Hemostasis / Wound Care Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Surgical Hemostatic Products
TypeHardware Sales
Description

Revenue from sale of FDA-cleared and developmental surgical hemostatic products including LifeGel, LifeFoam, LifeCoat, LifePatch, LifeFilm, and LifePutty for use in spine surgery, cardiac surgery, and trauma applications.

medcurainc.com
2Consumer Wound Care Products
TypeHardware Sales
Description

Revenue from over-the-counter consumer products including Rapid-Seal wound management gel sold through major retail chains (CVS, Walgreens, Walmart.com, Amazon) and Seal-It pet wound care gel.

medcurainc.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 9 records shown
1LifeGel
Description

Lead product - FDA Breakthrough Device Designated absorbable hemostatic gel for surgical bleeding control, particularly in spine surgery applications.

medcurainc.com
+8 more records
Core offering1 text field

Medcura develops and manufactures a portfolio of hemostatic products based on a proprietary hydrophobically modified chitosan biopolymer platform, including LifeGel (FDA Breakthrough Device Designated surgical gel), LifeFoam, LifeCoat, LifePatch, LifeFilm, and LifePutty for surgical bleeding control in spine, cardiac, trauma, and minimally invasive procedures. The company also sells consumer wound care products (Rapid-Seal) and pet wound care gel (Seal-It) through major retail and e-commerce channels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Resorbs in approximately 8-12 weeks after application
+2 more records
Product overview1 text field

Medcura is a medical device company developing a comprehensive LIFE™ Surgical Hemostasis Portfolio of hemostatic products based on a proprietary hydrophobically modified chitosan biopolymer platform. The flagship product is LifeGel™, the first and only absorbable hemostatic agent with FDA Breakthrough Device Designation for its no-swell properties, targeting the $2.5 billion global surgical hemostasis market with initial focus on spine surgery. The portfolio includes multiple product formats—gel (LifeGel), foam (LifeFoam), powder (LifeCoat), patch (LifePatch), film (LifeFilm), putty (LifePutty), sheet (LifeSheet), and fiber (LifeFib)—designed to address bleeding control across surgical, military/trauma, and consumer applications. The company also offers consumer products including Rapid-Seal™ wound management gel and Seal-It™ pet wound care gel sold through major retail channels. The company has received five FDA clearances (K172010, K143466, K192667, K182811, K180152) and two FDA Breakthrough Device Designations.

Product and service10 records
1LifeGel
CategorySurgical Hemostasis - Gel
Description

Flagship flowable absorbable hemostatic gel designed to control surgical bleeding without swelling, specifically developed for spinal surgery and other procedures where swelling cannot be tolerated. The first and only absorbable hemostatic agent to receive FDA Breakthrough Device Designation.

2LifeFoam
CategorySurgical Hemostasis - Foam
Description

Ready-to-use expanding hemostatic foam in syringe or spray form composed of modified chitosan designed to stop bleeding during trauma, orthopedic and plastic surgery scenarios. Targets severe traumatic bleeding and non-compressible injuries; received FDA Breakthrough Device Designation for traumatic wounds.

3LifeCoat
CategorySurgical Hemostasis - Powder
Description

Hemostatic powder delivered by bellows applicator during surgical procedures for minimal, mild, and moderate surgical bleeding. Positioned against existing absorbable hemostatic powders which are expensive and not designed for moderate surgical bleeding.

4LifePatch
5LifeFilm
6LifePutty
7LifeSheet
8LifeFib
9Rapid-Seal
10Seal-It
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

BD manufactures a broad portfolio of surgical hemostats and wound care products across its medical device segment. Its scale, sales infrastructure, and hospital relationships make it a significant competitor and potential strategic acquirer in the surgical hemostasis space.

TypeEmerging player
Description

Arch Therapeutics is a clinical-stage medical device company developing AC5, a self-assembling peptide hemostatic technology for surgical and trauma applications. It represents the closest emerging-stage analog to Medcura's clinical pathway and Breakthrough Designation strategy.

TypeDirect peer
Description

Baxter markets FloSeal Hemostatic Matrix, the dominant flowable surgical hemostat globally. Medcura's SVP Steve Ford previously grew FloSeal to $350M+ in sales, and Medcura's lead product LifeGel is positioned as a direct non-swelling alternative to FloSeal.

TypeBroad incumbent
Description

Ethicon manufactures the Surgicel, Surgiflo, and Evicel lines of surgical hemostats and sealants under the J&J MedTech umbrella. As the dominant surgical hemostat franchise globally, Surgiflo and Surgicel powder are the most direct competitors to Medcura's LifeGel and LifeCoat.

TypeBroad incumbent
Description

CSL Behring (CSL Limited subsidiary) markets fibrin sealant and other plasma-derived hemostatic products for surgical applications. Its biological hemostat portfolio and global hospital reach position it as an incumbent in the broader surgical bleeding control market.

TypeEmerging player
Description

Cohera Medical develops surgical adhesives and sealants (Sylys, TissuGlu) used in post-surgical applications. While focused on sealants rather than hemostats, the company's surgical specialty overlap and emerging commercial stage make it a comparable emerging medical device peer.

TypeDirect peer
Description

Integra offers a portfolio of surgical hemostats, dural sealants, and neurosurgical products that compete across multiple of Medcura's target segments including spine and neurosurgery. The company also provides regenerative tissue technologies relevant to orthopedic hemostasis.

TypeBroad incumbent
Description

Pfizer manufactures GelFoam absorbable gelatin sponge and powder, one of the oldest and most widely used surgical hemostat brands. GelFoam is explicitly cited on Medcura's website as a swelling competitor that LifeGel is positioned against.

TypeDirect peer
Description

Biom'Up developed HEMOBLAST Bellows, a surgical hemostatic powder delivered via bellows applicator that competes with Medcura's LifeCoat powder. Medcura's commercial advisor Dave Clark previously co-led the U.S. launch of HEMOBLAST at Biom'Up.

10CryoLife
TypeDirect peer
Description

CryoLife (now Artivion) markets BioGlue and other surgical hemostats/sealants used in cardiac and vascular surgery—directly overlapping with Medcura's cardiac surgery use cases for LifeGel and LifeFilm.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medcura

Surgical Hemostasis / Wound Care Medical Devicesmedcurainc.com

Medcura firmographics

Firmographics
Name
Medcura
Legal name
Medcura, Inc.
Website
https://medcurainc.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Medcura industry classification

Industry
Product category
Surgical Hemostasis / Wound Care Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYCRADAMAB
First Aid & Wound Care (Bandages, Dressings, Antiseptics, Burn Care)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

Keywords

  • Hemostatic agents
  • Wound care products
  • Surgical medical devices
  • Biopolymer hemostasis
  • Bleeding control solutions

Where Medcura is headquartered

Location

Headquarters

HQ city
Riverdale
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Medcura business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Surgical Hemostatic Products: Revenue from sale of FDA-cleared and developmental surgical hemostatic products including LifeGel, LifeFoam, LifeCoat, LifePatch, LifeFilm, and LifePutty for use in spine surgery, cardiac surgery, and trauma applications.
  2. Consumer Wound Care Products: Revenue from over-the-counter consumer products including Rapid-Seal wound management gel sold through major retail chains (CVS, Walgreens, Walmart.com, Amazon) and Seal-It pet wound care gel.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Medcura product offering

Product offering

Core offering

Medcura develops and manufactures a portfolio of hemostatic products based on a proprietary hydrophobically modified chitosan biopolymer platform, including LifeGel (FDA Breakthrough Device Designated surgical gel), LifeFoam, LifeCoat, LifePatch, LifeFilm, and LifePutty for surgical bleeding control in spine, cardiac, trauma, and minimally invasive procedures. The company also sells consumer wound care products (Rapid-Seal) and pet wound care gel (Seal-It) through major retail and e-commerce channels.

Product overview

Medcura is a medical device company developing a comprehensive LIFE™ Surgical Hemostasis Portfolio of hemostatic products based on a proprietary hydrophobically modified chitosan biopolymer platform. The flagship product is LifeGel™, the first and only absorbable hemostatic agent with FDA Breakthrough Device Designation for its no-swell properties, targeting the $2.5 billion global surgical hemostasis market with initial focus on spine surgery. The portfolio includes multiple product formats—gel (LifeGel), foam (LifeFoam), powder (LifeCoat), patch (LifePatch), film (LifeFilm), putty (LifePutty), sheet (LifeSheet), and fiber (LifeFib)—designed to address bleeding control across surgical, military/trauma, and consumer applications. The company also offers consumer products including Rapid-Seal™ wound management gel and Seal-It™ pet wound care gel sold through major retail channels. The company has received five FDA clearances (K172010, K143466, K192667, K182811, K180152) and two FDA Breakthrough Device Designations.

Differentiator

Problem solved

Functional benefit

Brands

  • LifeGel: Lead product - FDA Breakthrough Device Designated absorbable hemostatic gel for surgical bleeding control, particularly in spine surgery applications.
  • LifeFoam
  • LifeCoat
  • LifePatch
  • LifeFilm
  • LifePutty
  • LIFE Surgical Hemostasis Portfolio
  • Rapid-Seal
  • Seal-It

Products and services

  • LifeGel Flagship flowable absorbable hemostatic gel designed to control surgical bleeding without swelling, specifically developed for spinal surgery and other procedures where swelling cannot be tolerated. The first and only absorbable hemostatic agent to receive FDA Breakthrough Device Designation.
  • LifeFoam Ready-to-use expanding hemostatic foam in syringe or spray form composed of modified chitosan designed to stop bleeding during trauma, orthopedic and plastic surgery scenarios. Targets severe traumatic bleeding and non-compressible injuries; received FDA Breakthrough Device Designation for traumatic wounds.
  • LifeCoat Hemostatic powder delivered by bellows applicator during surgical procedures for minimal, mild, and moderate surgical bleeding. Positioned against existing absorbable hemostatic powders which are expensive and not designed for moderate surgical bleeding.
  • LifePatch
  • LifeFilm
  • LifePutty
  • LifeSheet
  • LifeFib
  • Rapid-Seal
  • Seal-It

Quantifiable outcome

  • Resorbs in approximately 8-12 weeks after application
  • +2 more outcomes

Companies that use Medcura

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles5 records

Medcura technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Medcura partnerships and signals

Strategic signal

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Medcura competitors and assessment

Company assessment

Broad incumbents

  • Becton Dickinson (BD): BD manufactures a broad portfolio of surgical hemostats and wound care products across its medical device segment. Its scale, sales infrastructure, and hospital relationships make it a significant competitor and potential strategic acquirer in the surgical hemostasis space.
  • Ethicon (Johnson & Johnson): Ethicon manufactures the Surgicel, Surgiflo, and Evicel lines of surgical hemostats and sealants under the J&J MedTech umbrella. As the dominant surgical hemostat franchise globally, Surgiflo and Surgicel powder are the most direct competitors to Medcura's LifeGel and LifeCoat.
  • CSL Behring: CSL Behring (CSL Limited subsidiary) markets fibrin sealant and other plasma-derived hemostatic products for surgical applications. Its biological hemostat portfolio and global hospital reach position it as an incumbent in the broader surgical bleeding control market.
  • Pfizer (GelFoam franchise): Pfizer manufactures GelFoam absorbable gelatin sponge and powder, one of the oldest and most widely used surgical hemostat brands. GelFoam is explicitly cited on Medcura's website as a swelling competitor that LifeGel is positioned against.

Emerging players

  • Arch Therapeutics: Arch Therapeutics is a clinical-stage medical device company developing AC5, a self-assembling peptide hemostatic technology for surgical and trauma applications. It represents the closest emerging-stage analog to Medcura's clinical pathway and Breakthrough Designation strategy.
  • Cohera Medical: Cohera Medical develops surgical adhesives and sealants (Sylys, TissuGlu) used in post-surgical applications. While focused on sealants rather than hemostats, the company's surgical specialty overlap and emerging commercial stage make it a comparable emerging medical device peer.

Direct peers

  • Baxter International: Baxter markets FloSeal Hemostatic Matrix, the dominant flowable surgical hemostat globally. Medcura's SVP Steve Ford previously grew FloSeal to $350M+ in sales, and Medcura's lead product LifeGel is positioned as a direct non-swelling alternative to FloSeal.
  • Integra LifeSciences: Integra offers a portfolio of surgical hemostats, dural sealants, and neurosurgical products that compete across multiple of Medcura's target segments including spine and neurosurgery. The company also provides regenerative tissue technologies relevant to orthopedic hemostasis.
  • Biom'Up: Biom'Up developed HEMOBLAST Bellows, a surgical hemostatic powder delivered via bellows applicator that competes with Medcura's LifeCoat powder. Medcura's commercial advisor Dave Clark previously co-led the U.S. launch of HEMOBLAST at Biom'Up.
  • CryoLife: CryoLife (now Artivion) markets BioGlue and other surgical hemostats/sealants used in cardiac and vascular surgery—directly overlapping with Medcura's cardiac surgery use cases for LifeGel and LifeFilm.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Medcura social profiles

Digital presence

Medcura compliance and trust

Trust signal

Compliance7 records

Medcura financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medcura leadership team

Management profile

Number of profiles

Profiles15 records

Medcura funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medcura M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medcura

What does Medcura do?

Medcura develops and manufactures a portfolio of hemostatic products based on a proprietary hydrophobically modified chitosan biopolymer platform, including LifeGel (FDA Breakthrough Device Designated surgical gel), LifeFoam, LifeCoat, LifePatch, LifeFilm, and LifePutty for surgical bleeding control in spine, cardiac, trauma, and minimally invasive procedures. The company also sells consumer wound care products (Rapid-Seal) and pet wound care gel (Seal-It) through major retail and e-commerce channels.

Is Medcura a public or private company?

Medcura is a private company. It is classified as venture growth investor backed and is currently operating.

When was Medcura founded?

Medcura was founded in 2019. It employs 11 to 50 people.

Where is Medcura based?

Medcura is headquartered in Riverdale, United States, in the North America region.

How does Medcura make money?

Two revenue lines are on record. Surgical Hemostatic Products are the primary driver. The others are consumer Wound Care Products.

Who are Medcura's main competitors?

Broad incumbents on record are Becton Dickinson (BD), Ethicon (Johnson & Johnson), CSL Behring and Pfizer (GelFoam franchise). Emerging players are Arch Therapeutics and Cohera Medical. Direct peers are Baxter International, Integra LifeSciences, Biom'Up and CryoLife.

Does Medcura have an API?

No public API is recorded for Medcura.

What industry is Medcura in?

Medcura's product category is Surgical Hemostasis / Wound Care Medical Devices. Its primary akta.pro industry code is CRADAMAB, First Aid & Wound Care (Bandages, Dressings, Antiseptics, Burn Care). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
RyorthoMedcura Appoints Medical Device Industry Veteran Gary P. Fischetti to Board of DirectorsMedcura, Inc. announced the appointment of Gary P. Fischetti, a medical device industry veteran with over 35 years of experience including senior executive roles at Johnson & Johnson's Ethicon and DePuy Synthes businesses, to its Board of Directors. Fischetti's expertise in innovation, regulatory strategy, and global commercialization is expected to advance LifeGel™ through pivotal pre-clinical and human clinical trials toward U.S. and global market commercialization. LifeGel™ is the first and only absorbable hemostatic agent to receive FDA Breakthrough Device Designation for its non-swelling properties.citybizMedcura Appoints Medical Device Veteran Gary P. Fischetti to Board of DirectorsMedcura, Inc. appointed medical device veteran Gary P. Fischetti to its Board of Directors, bringing over three decades of global medtech experience as the company advances its surgical hemostasis platform. Fischetti, formerly a senior executive at Johnson & Johnson including leadership roles at Ethicon and DePuy Synthes, joins as Medcura prepares to expand clinical testing for LifeGel, its FDA-designated absorbable hemostatic gel. The appointment signals Medcura's push toward commercialization in the U.S. and global markets for a product that has received Breakthrough Device designation from the FDA.PR NewswireMedcura Appoints Medical Device Industry Veteran Gary P. Fischetti to Board of DirectorsMedcura, Inc., a developer of hemostatic technologies and maker of LifeGel absorbable hemostatic gel, appointed Gary P. Fischetti to its Board of Directors on May 1, 2026. Fischetti brings over 35 years of medical technology leadership experience, including senior executive roles at Johnson & Johnson within its Ethicon and DePuy Synthes businesses. The appointment is intended to provide guidance as Medcura advances LifeGel through pivotal pre-clinical studies and into human clinical trials toward U.S. and global commercialization.PR NewswireMEDCURA'S HEMOSTATIC AGENT LIFEGEL™ WINS 2024 SPINE TECHNOLOGY AWARDMedcura, Inc. received the 2024/2025 Best Technology in Spine Award from Orthopedics This Week for its LifeGel Absorbable Hemostatic Gel, accepted at the North American Spine Society meeting in Chicago. The product, which has FDA Breakthrough Device Designation, addresses a $1.1 billion segment of the surgical hemostat market and is designed to achieve hemostasis during spinal surgery without the swelling risk associated with current agents that can cause post-operative neurologic deficits.FinSMEsMedcura Closes $22.4M in FundingMedcura, a medical device developer based in Maryland, closed a $22.4 million convertible debt financing round to accelerate the development of its lead surgical product, LifeGel™. The company intends to use these funds to advance its product into pivotal clinical trials and prepare for global commercialization within the biosurgery market.MedcuraincMedcura Closes $22.4 Million Financing to Accelerate Development of Surgical Hemostatic Gel and Surgical Hemostasis PortfolioMedcura, Inc. closed a $22.4 million private placement in convertible debt to accelerate the development of its surgical hemostatic gel, LifeGel™. The company intends to use these funds to complete pre-clinical testing and file an Investigational Device Exemption with the U.S. FDA for global studies on stopping bleeding in spinal surgery. This financing supports Medcura's strategy to commercialize its non-swelling hemostatic technology in the $2.8 billion biosurgery market.PR NewswireMedcura Closes $22.4 Million Financing to Accelerate Development of Surgical Hemostatic Gel and Surgical Hemostasis PortfolioMedcura, Inc. has closed a private placement of convertible debt raising $22.4 million to accelerate the development of its LifeGel surgical hemostatic gel. The company intends to use these funds to complete pre-clinical testing and file an Investigational Device Exemption with the U.S. FDA for global studies in spinal surgery. This financing supports Medcura's strategy to commercialize its lead product within the $2.8 billion worldwide biosurgery market.PR NewswireMedcura Names Barry, McAfee to Leadership PositionsMedcura Inc. announced the appointment of Dr. John Barry as Group Vice President of R&D and Operations and J.P. McAfee as Vice President of Legal Affairs and Compliance to support acceleration toward pivotal trials and global commercialization of its LifeGel™ Absorbable Flowable Hemostatic Gel and broader Medcura Life™ platform. Dr. Barry brings over 20 years of experience including prior roles at Miromatrix Medical and Baxter Advanced Surgery, while McAfee joins from Biom'up USA and Globus Medical with eight years of legal expertise in the medical device sector. The company stated it aims to compete in 85% of the over $2.5 billion market for surgical hemostatic products with what it describes as high-efficacy, high-safety, and low-cost offerings.citybizMedcura Appoints Jacob Rodman to Board of DirectorsMedcura Inc. announced the appointment of Jacob Rodman, CEO of Raleigh Neurosurgical Clinic and president-elect of Nerves (Neurosurgery Executives Resource Value & Education Society), to its Board of Directors. Rodman is expected to provide strategic guidance for the commercialization of LifeGel™, Medcura's flagship surgical hemostatic product that received FDA Breakthrough Device Designation for spine surgeries due to its no-swell feature reducing nerve damage risks. Medcura offers consumer products including Rapid-Seal™ wound gel at major retailers and recently launched Seal-It™ pet wound care gel.PR NewswireAccomplished Scientist and Biosurgery Industry Veteran Dr. Neil Winterbottom Joins Medcura's Leadership TeamMedcura, Inc. has appointed Dr. Neil Winterbottom as its new Senior Vice President of Product Development & Manufacturing Operations to drive the FDA approval and commercialization of LifeGel™ for spine surgery indications. LifeGel™ is the first and only surgical hemostatic agent to receive the FDA's Breakthrough Device Designation, distinguishing itself through a no-swelling innovation that addresses a critical safety concern in spinal procedures where existing swelling agents have been linked to nerve damage and paralysis.